Literature DB >> 23227077

Four Year Trend of Carbapenem-Resistance in Newly Opened ICUs of a University-Affiliated Hospital of South Korea.

Bo Min Kim1, Eun Ju Jeon, Ju Young Jang, Jin-Won Chung, Jihoon Park, Jae Chol Choi, Jong Wook Shin, In Won Park, Byoung Whui Choi, Jae Yeol Kim.   

Abstract

BACKGROUND: Carbapenem-resistance is rapidly evolving among the pathogenic microbes in intensive care units (ICUs). This study aimed to determine annual trend of carbapenem-resistance in the ICU for 4 years, since the opening of a university-affiliated hospital in South Korea.
METHODS: From 2005 to 2008, microbial samples from consecutive 6,772 patients were screened in the ICU. Three hundred and ninety-seven patients (5.9%) and their first isolates of carbapenem-resistant pathogens were analyzed.
RESULTS: The percentage of patients infected with carbapenem-resistant organisms increased constantly during the initial three years (2.3% in 2005, 6.2% in 2006, 7.8% in 2007), then it declined to 6.5% in 2008. Acute Physiology and Chronic Health Evaluation (APACHE) III score at admission was 58.0±23.5, the median length of the ICU stay was 37 days, and the mortality rate was 37.5%. The sampling sites were endotracheal suction (67%), catheterized urine (17%), wound (6%) and others (10%). Bacteria with carbapenem-resistance were Pseudomonas aeruginosa (247 isolates, 62%), Acinetobacter baumannii (117 isolates, 30%), Enterobacteriaceae (12 isolates, 3%), and others (21, 5%). Of note, peak isolation of carbapenem-resistant microorganisms in medical ICU was followed by the same epidemic at surgical ICU.
CONCLUSION: Taken together, carbapenem-resistant pathogens are of growing concern in the ICU.

Entities:  

Keywords:  Carbapenems; Drug Resistance, Bacterial; Intensive Care Units

Year:  2012        PMID: 23227077      PMCID: PMC3510287          DOI: 10.4046/trd.2012.72.4.360

Source DB:  PubMed          Journal:  Tuberc Respir Dis (Seoul)        ISSN: 1738-3536


  16 in total

1.  Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).

Authors:  Paul R Rhomberg; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2006-09-01       Impact factor: 2.803

2.  Outbreak of multiple clones of imipenem-resistant Acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit.

Authors:  S Pournaras; A Markogiannakis; A Ikonomidis; L Kondyli; K Bethimouti; A N Maniatis; N J Legakis; A Tsakris
Journal:  J Antimicrob Chemother       Date:  2006-01-23       Impact factor: 5.790

3.  Epidemiology, risk factors and outcome of nosocomial infections in a Respiratory Intensive Care Unit in North India.

Authors:  Ritesh Agarwal; Dheeraj Gupta; Pallab Ray; Ashutosh N Aggarwal; Surinder K Jindal
Journal:  J Infect       Date:  2005-12-15       Impact factor: 6.072

4.  Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of beta-lactam resistance.

Authors:  V Dubois; C Arpin; M Melon; B Melon; C Andre; C Frigo; C Quentin
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

Review 5.  OXA (beta)-lactamases in Acinetobacter: the story so far.

Authors:  Susan Brown; Sebastian Amyes
Journal:  J Antimicrob Chemother       Date:  2005-12-06       Impact factor: 5.790

6.  Alert surveillance of intensive care unit-acquired Acinetobacter infections in a Sicilian hospital.

Authors:  A Agodi; R Zarrilli; M Barchitta; A Anzaldi; A Di Popolo; A Mattaliano; E Ghiraldi; S Travali
Journal:  Clin Microbiol Infect       Date:  2006-03       Impact factor: 8.067

7.  Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia.

Authors:  M P Crespo; N Woodford; A Sinclair; M E Kaufmann; J Turton; J Glover; J D Velez; C R Castañeda; M Recalde; D M Livermore
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

8.  Overview of nosocomial infections caused by gram-negative bacilli.

Authors:  Robert Gaynes; Jonathan R Edwards
Journal:  Clin Infect Dis       Date:  2005-08-16       Impact factor: 9.079

9.  Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases.

Authors:  David L Paterson; Wen-Chien Ko; Anne Von Gottberg; Sunita Mohapatra; Jose Maria Casellas; Herman Goossens; Lutfiye Mulazimoglu; Gordon Trenholme; Keith P Klugman; Robert A Bonomo; Louis B Rice; Marilyn M Wagener; Joseph G McCormack; Victor L Yu
Journal:  Clin Infect Dis       Date:  2004-06-08       Impact factor: 9.079

10.  Antimicrobial resistance surveillance of bacteria in 1999 in Korea with a special reference to resistance of enterococci to vancomycin and gram-negative bacilli to third generation cephalosporin, imipenem, and fluoroquinolone.

Authors:  K Lee; H S Lee; S J Jang; A J Park; M H Lee; W K Song; Y Chong
Journal:  J Korean Med Sci       Date:  2001-06       Impact factor: 2.153

View more
  4 in total

1.  Are Community-Based Hospitals Safe from Carbapenem-Resistant Enterobacteriaceae in Korea?

Authors:  Chang Seop Lee
Journal:  Infect Chemother       Date:  2016-09

2.  Rapid detection of Pseudomonas aeruginosa and Acinetobacter baumannii Harboring bla(VIM-2), bla(IMP-1) and bla(OXA-23) genes by using loop-mediated isothermal amplification methods.

Authors:  Hye Jin Kim; Hyung Sun Kim; Jae Myun Lee; Sang Sun Yoon; Dongeun Yong
Journal:  Ann Lab Med       Date:  2016-01       Impact factor: 3.464

3.  Carbapenem-resistant Enterobacteriaceae: Prevalence and Risk Factors in a Single Community-Based Hospital in Korea.

Authors:  Hyo Jin Lee; Jae Ki Choi; Sung Yeon Cho; Si Hyun Kim; Sun Hee Park; Su Mi Choi; Dong Gun Lee; Jung Hyun Choi; Jin Hong Yoo
Journal:  Infect Chemother       Date:  2016-09-08

4.  Positivity of Carbapenemase-producing Enterobacteriaceae in Patients Following Exposure within Long-term Care Facilities in Seoul, Korea.

Authors:  Jin Ju Park; Yu Bin Seo; Jacob Lee; Joong Sik Eom; Wonkeun Song; Young Kyun Choi; Sung Ran Kim; Hee Jung Son; Nan Hyoung Cho
Journal:  J Korean Med Sci       Date:  2020-09-14       Impact factor: 2.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.